Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17137872 | 0.84 | DPP4 (0.33) | DPP4DPP7 | |
| SCHEMBL17137865 | 0.83 | DPP4 (0.35) | DPP4DPP7 | |
| SCHEMBL2470441 | 0.81 | DPP4 (0.35) | DPP4MAPTNPC1CASP3RAB9A | |
| SCHEMBL17137867 | 0.81 | DPP4 (0.31) | DPP4DPP7 | |
| SCHEMBL17137856 | 0.80 | DPP4 (0.33) | DPP4ADAMTS4ADAMTS5MMP3DPP7 | |
| SCHEMBL3533168 | 0.80 | DPP4 (0.43) | DPP4MAPTADAMTS4ADAMTS5MMP3 | |
| SCHEMBL17137855 | 0.80 | DPP4 (0.33) | DPP4ADAMTS4ADAMTS5MMP3DPP7 | |
| SCHEMBL12477152 | 0.80 | DPP4 (0.33) | DPP4DPP7ALDH1A1 | |
| SCHEMBL17137854 | 0.80 | DPP4 (0.33) | DPP4DPP7 | |
| SCHEMBL17137877 | 0.79 | DPP4 (0.30) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718667-B2 | Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080009510-A1 | Fused Aminopiperidine as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009510-A1 | Fused Aminopiperidine as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885MAPT 3208/4885NPC1 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.